γ-谷氨酰转肽酶水平与慢性肺源性心脏病及心肺功能相关性研究
|
摘要
目的:探讨γ-谷氨酰转肽酶水平与慢性肺源性心脏病及心肺功能之间的关系。方法:将2018年1月-2019年1月笔者所在医院收治的60例慢性肺源性心脏病患者作为研究对象,分为急性发作期、临床缓解期,每组30例。另选取健康体检者30例。对比γ-谷氨酰转肽酶水平与慢性肺源性心脏病及心肺功能之间的关系规律。结果:急性发作期组、临床缓解期组γ-谷氨酰转肽酶水平均已超过正常数值,高于健康组;研究显示γ-谷氨酰转肽酶水平对FEV_1/FVC%有着一定的影响,且变化规律为γ-谷氨酰转肽酶水平越高,FEV_1/FVC%指标逐渐降低,差异具有统计学意义(P<0.05)。显示心功能NYHA级别越高,γ-谷氨酰转肽酶水平也随之越高,数据呈正相关(r=0.283,P=0.003)。结论:对于慢性肺源性心脏病患者,测定其血清γ-谷氨酰转肽酶水平,结果显示血清γ-谷氨酰转肽酶水平变化与患者心肺相关指标、病情变化历程等有一定的相关性,值得在临床上进一步开展并进行研究。
Objective:To investigate the relationship between the level of gamma-glutamyltransferase and chronic pulmonary heart disease(CPHD) and cardiopulmonary function.Method:From January 2018 to January 2019,60 patients with chronic pulmonary heart disease admitted to our hospital were divided into acute attack stage,clinical remission stage,30 cases in each group.and 30 health examination people were selected as the health group,To compare the relationship between the level of gamma-glutamyltransferase and chronic pulmonary heart disease and cardiopulmonary function.Result:The levels of gammaglutamyltransferase in acute episode group and clinical remission group were higher than those in normal group,and higher than those in healthy group.Studies showed that the level of gamma-glutamyltransferase had a certain effect on FEV_1/FVC% and the change rule was that the higher the level of gammaglutamyltransferase,the lower the FEV_1/FVC% index,the difference was statistically significant(P<0.05).The higher the NYHA level of cardiac function was,the higher the level of gamma-glutamyltransferase.The data were positively correlated(r=0.283,P=0.003).Conclusion:For patients with chronic pulmonary heart disease,the serum level of gamma-glutamyltransferase is measured.The results show that the changes of serum level of gamma-glutamyltransferase are correlated with the related indexes of heart and lung and the course of the disease,which deserve further study in clinic.
Objective:To investigate the relationship between the level of gamma-glutamyltransferase and chronic pulmonary heart disease(CPHD) and cardiopulmonary function.Method:From January 2018 to January 2019,60 patients with chronic pulmonary heart disease admitted to our hospital were divided into acute attack stage,clinical remission stage,30 cases in each group.and 30 health examination people were selected as the health group,To compare the relationship between the level of gamma-glutamyltransferase and chronic pulmonary heart disease and cardiopulmonary function.Result:The levels of gammaglutamyltransferase in acute episode group and clinical remission group were higher than those in normal group,and higher than those in healthy group.Studies showed that the level of gamma-glutamyltransferase had a certain effect on FEV_1/FVC% and the change rule was that the higher the level of gammaglutamyltransferase,the lower the FEV_1/FVC% index,the difference was statistically significant(P<0.05).The higher the NYHA level of cardiac function was,the higher the level of gamma-glutamyltransferase.The data were positively correlated(r=0.283,P=0.003).Conclusion:For patients with chronic pulmonary heart disease,the serum level of gamma-glutamyltransferase is measured.The results show that the changes of serum level of gamma-glutamyltransferase are correlated with the related indexes of heart and lung and the course of the disease,which deserve further study in clinic.
引文
[1]杜伟.血浆脑钠肽水平在慢性肺源性心脏病诊断中的临床意义[J].中国循证心血管医学杂志,2017,9(5):591-593.
[2]周平,孙洪岩.米力农对慢性阻塞性肺疾病引起慢性肺源性心脏病合并右心衰临床疗效观察[J].安徽医药,2017,21(1):136-139.
[3]卜丽娜,宋爱玲,贾卫红,等.法舒地尔治疗老年慢性肺源性心脏病临床疗效及其机制的随机对照研究[J].中国全科医学,2017,20(5):538-542.
[4]任玉军.左卡尼汀联合参麦注射液对慢性肺源性心脏病合并心力衰竭患者心功能的影响[J].河北医学,2016,22(12):2063-2065.
[5]苟连平,刘世平,方志远.心脑欣治疗慢性肺源性心脏病患者的临床疗效及机制研究[J].中国全科医学,2016,19(1):406-408.
[6]卢冠男,孙宏.血浆脑钠肽水平监测在慢性肺源性心脏病患者中的临床价值[J].中国地方病防治杂志,2016,31(10):1138-1139.
[7]邢阿光,黄贤胜,夏爽,等.不同病因心力衰竭患者血清脑钠肽水平观察[J].山东医药,2016,56(27):70-72.
[8]张建,杨林飞,孙桂兰,等.左卡尼丁对急性心肌损伤的保护作用[J].热带医学杂志,2016,16(6):789-792.
[9]何晶,赵勤华,王岚,等.丹红注射液治疗慢性肺源性心脏病患者30例临床观察[J].中医临床研究,2016,8(18):40-42.
[10]王玮,张春峰,徐辉,等.慢性肺源性心脏病合并急性左心衰竭治疗中应用无创机械通气的效果观察[J].陕西医学杂志,2017,46(4):430-431.
[11]方译,唐其柱,卞洲艳,等.左卡尼丁治疗扩张型心肌病的Meta分析[J].中国循证心血管医学杂志,2012,4(2):101-105.
[12]郭玲玲,卢其玲,童波,等.丹参酮ⅡA对慢性阻塞性肺疾病继发性肺动脉高压疗效的影响[J].实用临床医学,2016,17(2):1-3,7.
[2]周平,孙洪岩.米力农对慢性阻塞性肺疾病引起慢性肺源性心脏病合并右心衰临床疗效观察[J].安徽医药,2017,21(1):136-139.
[3]卜丽娜,宋爱玲,贾卫红,等.法舒地尔治疗老年慢性肺源性心脏病临床疗效及其机制的随机对照研究[J].中国全科医学,2017,20(5):538-542.
[4]任玉军.左卡尼汀联合参麦注射液对慢性肺源性心脏病合并心力衰竭患者心功能的影响[J].河北医学,2016,22(12):2063-2065.
[5]苟连平,刘世平,方志远.心脑欣治疗慢性肺源性心脏病患者的临床疗效及机制研究[J].中国全科医学,2016,19(1):406-408.
[6]卢冠男,孙宏.血浆脑钠肽水平监测在慢性肺源性心脏病患者中的临床价值[J].中国地方病防治杂志,2016,31(10):1138-1139.
[7]邢阿光,黄贤胜,夏爽,等.不同病因心力衰竭患者血清脑钠肽水平观察[J].山东医药,2016,56(27):70-72.
[8]张建,杨林飞,孙桂兰,等.左卡尼丁对急性心肌损伤的保护作用[J].热带医学杂志,2016,16(6):789-792.
[9]何晶,赵勤华,王岚,等.丹红注射液治疗慢性肺源性心脏病患者30例临床观察[J].中医临床研究,2016,8(18):40-42.
[10]王玮,张春峰,徐辉,等.慢性肺源性心脏病合并急性左心衰竭治疗中应用无创机械通气的效果观察[J].陕西医学杂志,2017,46(4):430-431.
[11]方译,唐其柱,卞洲艳,等.左卡尼丁治疗扩张型心肌病的Meta分析[J].中国循证心血管医学杂志,2012,4(2):101-105.
[12]郭玲玲,卢其玲,童波,等.丹参酮ⅡA对慢性阻塞性肺疾病继发性肺动脉高压疗效的影响[J].实用临床医学,2016,17(2):1-3,7.